Nanjing Hicin Pharmaceutical Co Ltd
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for … Read more
Market Cap & Net Worth: Nanjing Hicin Pharmaceutical Co Ltd (300584)
Nanjing Hicin Pharmaceutical Co Ltd (SHE:300584) has a market capitalization of $672.02 Million (CN¥4.93 Billion) as of March 26, 2026. Listed on the SHE stock exchange, this China-based company holds position #13233 globally and #3337 in its home market, demonstrating a -5.30% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanjing Hicin Pharmaceutical Co Ltd's stock price CN¥41.09 by its total outstanding shares 120000000 (120.00 Million).
Nanjing Hicin Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Nanjing Hicin Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $339.62 Million to $672.02 Million (16.39% CAGR).
Nanjing Hicin Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanjing Hicin Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.65x
Nanjing Hicin Pharmaceutical Co Ltd's market cap is 0.65 times its annual revenue
0.97x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
8.20x
Nanjing Hicin Pharmaceutical Co Ltd's market cap is 8.20 times its annual earnings
9.49x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $339.62 Million | $455.03 Million | $65.60 Million | 0.75x | 5.18x |
| 2018 | $380.88 Million | $711.91 Million | $83.22 Million | 0.54x | 4.58x |
| 2019 | $448.14 Million | $924.54 Million | $97.26 Million | 0.48x | 4.61x |
| 2020 | $329.93 Million | $706.30 Million | $55.23 Million | 0.47x | 5.97x |
| 2021 | $323.68 Million | $578.32 Million | $285.88 Million | 0.56x | 1.13x |
| 2022 | $524.94 Million | $526.47 Million | $32.45 Million | 1.00x | 16.18x |
| 2023 | $379.52 Million | $517.83 Million | $36.32 Million | 0.73x | 10.45x |
| 2024 | $329.72 Million | $504.36 Million | $40.22 Million | 0.65x | 8.20x |
Competitor Companies of 300584 by Market Capitalization
Companies near Nanjing Hicin Pharmaceutical Co Ltd in the global market cap rankings as of March 26, 2026.
Key companies related to Nanjing Hicin Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #421 globally with a market cap of $51.33 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #433 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #726 globally with a market cap of $27.67 Billion USD ( CN¥203.05 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #421 | Zoetis Inc | NYSE:ZTS | $51.33 Billion | $116.71 |
| #433 | Haleon plc | NYSE:HLN | $49.87 Billion | $9.74 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #726 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $27.67 Billion | CN¥54.10 |
Nanjing Hicin Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Nanjing Hicin Pharmaceutical Co Ltd's market cap moved from $339.62 Million to $ 672.02 Million, with a yearly change of 16.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥672.02 Million | -18.18% |
| 2025 | CN¥821.34 Million | +149.11% |
| 2024 | CN¥329.72 Million | -13.12% |
| 2023 | CN¥379.52 Million | -27.70% |
| 2022 | CN¥524.94 Million | +62.18% |
| 2021 | CN¥323.68 Million | -1.89% |
| 2020 | CN¥329.93 Million | -26.38% |
| 2019 | CN¥448.14 Million | +17.66% |
| 2018 | CN¥380.88 Million | +12.15% |
| 2017 | CN¥339.62 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 26th, 2026 the market cap of Nanjing Hicin Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $672.02 Million USD |
| MoneyControl | $672.02 Million USD |
| MarketWatch | $672.02 Million USD |
| marketcap.company | $672.02 Million USD |
| Reuters | $672.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.